What risk level is Mianserin for workers compensation claims?

Mianserin is classified as Moderate risk (3 risk points) by AllMeds. Tetracyclic antidepressant with significant sedating effects and potential for cognitive impairment.

Can you work or drive while taking Mianserin?

Mianserin is a CNS depressant that may cause sedation, drowsiness, and impaired coordination. It can affect driving ability and work capacity, particularly in safety-sensitive roles. Work capacity should be assessed on a case-by-case basis.

What should a case manager know about Mianserin?

Case managers should note that Mianserin is Moderate risk. It is a CNS depressant that may affect work capacity. Always check for drug interactions with other medications on the claim.

Antidepressant_other | Moderate Risk

Mianserin (Lumin 10)

Q: What schedule is Mianserin in Australia?

Mianserin is classified as S4 under the Therapeutic Goods Administration (TGA) in Australia.

What to know about Mianserin — also sold as Lumin 10, Lumin 20: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

Mianserin (brand names: Lumin 10, Lumin 20) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Tetracyclic antidepressant with significant sedating effects and potential for cognitive impairment.

Key Takeaways

TGA Schedule: S4 in Australia
Risk level: Moderate (3 points)
CNS depressant: May cause sedation, impair driving, and affect work capacity
PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme

Scheduling and Classification

Jurisdiction	Classification	Status
Australia (TGA)	S4	PBS listed

Risk Profile

Risk Level Moderate

Risk Points 3

CNS Depressant Yes

Respiratory Risk No

Tetracyclic antidepressant with significant sedating effects and potential for cognitive impairment.

How Mianserin is regulated

Mianserin is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Work capacity impact: As a CNS depressant, Mianserin may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.

Australia TGA / PBS / State Schemes

Classified as S4 under the Therapeutic Goods Administration (TGA).

Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.

United Kingdom NICE / MHRA / FPM

NICE guidelines recommend certain antidepressants (amitriptyline, duloxetine) for chronic pain management. For personal injury claims, antidepressant prescribing should be assessed for injury relatedness.

UK drug driving laws (Section 5A Road Traffic Act 2006) set specific limits for prescription drugs that cause impairment. Employers and occupational health advisors should assess fitness to work.

Check this medication against your full medication list

Run a full risk assessment including Mianserin interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Try it free → Talk to Sales →

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.